Global Carrier Screening Market Size, Share, Forecast Report, 2020-2027

Global Carrier Screening Market is expected to hold a value of about USD 4,200 Million by 2025 and is projected to register a CAGR of 16.8% from 2019 to 2025.
Carrier screening is a type of genetic test that is performed to determine the carries gene responsible for genetic disorders. This test is mostly carried out during pregnancy, as it provides life-long information about an individual's reproductive risk and their chances of having a child with a genetic disorder.

There is a number of different market player for carrier screening dominates the market which includes Eurofins Scientific and Illumina Inc. However, the scenario has changed in the last few years as the demand for these products is increasing. As a result, the manufacturing companies are getting involved in developing technologically advance carrier screening products.
Segmentation

By Services and Products

Product: The product segment holds the market in the carrier screening market. There is an increase in the segmental growth owing to the increasing use of these products during pregnancy to determine the early diagnosis and raising awareness about these diseases positively influences the market growth.
Services: It is the fastest-growing segment owing to the increasing number of laboratories adopting these services.
By Type

Expanded Carrier Screening: The expanded carrier screening is further segmented into predesigned panel testing and customized panel testing. It is the largest segment in the global carrier screening market. More than 100 different disorders can be scanned using expanded carrier screening using a single sample, which increases the demand for this product.
Targeted Carrier Screening: In this method, the tests are done based on ethnicity or family history. Targeted disease carrier screening is recommended for people who have a family history of a specific disorder, regardless of their race or ethnicity
By Medical Condition

Pulmonary Conditions: Pulmonary condition is the fastest-growing segment in the global carrier screening market. The increasing awareness about cystic fibrosis a pulmonary genetic disorder boosts segmental growth.
Hematological Conditions: This is expected to be the largest segment. Due to a large number of patients facing sickle cell disease, thalassemia, and others. It is estimated that globally 275,000 people have a sickle-cell disorder who needs early diagnosis and prophylaxis. Additionally, about 56 000 suffers from having major thalassemia.
Neurological Conditions: These are an inherited disorder causing mental disability, usually in children around 5-year-old. Tay–Sachs disease and Fragile X Syndrome is an example of an inherited neurological condition.
Others: The other segment includes down syndrome, trisomy 13, Marfan syndrome (MFS) and among others.

Key Players

• Eurofins Scientific (Luxembourg)
• Invitae Corporation (US)
• Opko Health (US)
• Fulgent Genetics Inc (US)
• Quest Diagnostics Incorporated (US)
• Sema4 (US)
• Myriad Genetics (US)
• Illumina Inc (US)
• Thermo Fisher Scientific Inc (US)
• Luminex Corporation (US)
• Natera Inc (US)
• Laboratory Corporation of America Holdings (US)